Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A feasibility study of a vestibular rehabilitation program in a sample of cognitively impaired clinical patients to guide future trials.
This is a feasibility study to gather preliminary data on a vestibular rehabilitation program. All participants who visit UHN memory clinic with a diagnosis of mild/moderate cognitive impairment due to Alzheimer's or vascular disease or both and have had falls will be asked to participate. If agree to be contacted they will receive a consent form.
All agreeable participants shall be screened for vestibular impairment through the following tests: Dix-Hall pike test, Head Impulse Test, Head Shake test, test of Dynamic Visual Acuity. In addition, participants will complete the MoCA to assess cognitive functioning. A score lower than 15 will exclude the participant.
After determining the population who is eligible for this study and willing to participate, participants shall move to baseline assessment. At baseline, measurements of balance, gait, and dynamic visual acuity in addition to questionnaires about dizziness felt, confidence in performing activities without falling, depression and quality of life, shall be completed.
Immediately after baseline, participants will begin their treatment arm, depending on if they have been put in the vestibular group or control group. Participants in the vestibular arm will be taught vestibular exercises and asked to perform vestibular exercises for 3 sessions daily, 3-10 minutes/session. Participation in vestibular exercises shall be recorded via a log by their caregiver. During the 12 weeks, these diaries shall be kept with the participant caregiver. Caregivers shall be followed up bi-weekly to ensure that participants are completing the exercises, and logging their participation.
At the end of the 12 weeks, participants will be reassessed with the same measures from baseline in addition to the head impulse test and test of dynamic visual acuity. The investigators shall also administer a final questionnaire (Problematic Experiences of Therapy Scale) to see what may have prevented completion of therapy or caused issues.
Participants that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
3-months after final assessments (6 months after start), all participants shall be contacted to see if there were any falls/near fall experiences.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vestibular Training (Intervention Group) | Experimental | For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions). These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns) |
|
| Usual Care (Control group) | No Intervention | Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vestibular Training (Intervention Group) | Behavioral | Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of falls/near fall experiences through the Falls Video Analysis Questionnaire (FVAQ) | Measured by comparing the test score change from baseline to follow up at 3 months and again at 6 months to determine if the therapy worked | 3 months and again 6 months after baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Change in levels of dizziness through the Dizziness Handicap Inventory (DHI) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in perceived level of confidence through the Activities Specific Balance Confidence Scale (ABC) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maria C Tartaglia, MD, FRCPC | University Health Network, Toronto | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Toronto Western Hospital | Toronto | Ontario | M5T 2S8 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| D015140 | Dementia, Vascular |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Measured by comparing the test score change from baseline to follow up at 3 months |
| 3 months |
| Change in quality of life through The Geriatric Depression Scale (GDS) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Cognitive status through the Montreal Cognitive Assessment (MoCA) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in physical functioning through the head impulse test (HIT) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Number of patients who can successfully complete Head Impulse Test (HIT) | Shall be measured by proportion of participants completing test (did not need to stop for any reason) | 3 months |
| Number of patients who can successfully complete Head Shake Test (HST) | Shall be measured by proportion of participants completing test (did not need to stop for any reason) | 3 months |
| Number of patients who can successfully complete Dynamic Gait Index (DGI) | Shall be measured by proportion of participants completing test (did not need to stop for any reason) | 3 months |
| Number of patients who can successfully complete the test of dynamic visual acuity (DVA) | Shall be measured by proportion of participants completing test (did not need to stop for any reason) | 3 months |
| Number of patients who can successfully complete the modified clinical test of sensory interaction on balance (mCTSIB) | Shall be measured by proportion of participants completing test (did not need to stop for any reason) | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Dizziness Handicap Inventory (DHI) | Shall be measured by percentage of test items completed | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Montreal Cognitive Assessment (MoCA) | Shall be measured by percentage of test items completed | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Quality of Life in Alzheimer's Disease (QOL-AD) | Shall be measured by percentage of test items completed | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the World Health Organization Quality of Life - BREF (WHOQOL-BREF) | Shall be measured by percentage of test items completed | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Activities Specific Balance Confidence scale (ABC) | Shall be measured by percentage of test items completed | 3 months |
| Completeness of questionnaires and which questions were: skipped, missed or difficult to understand for the Geriatric Depression Scale (GDS) | Shall be measured by percentage of test items completed | 3 months |
| Number of patients who successfully adhered to the vestibular rehabilitation program through the Problematic Experiences of Therapy scale (PETs) | filled out by both, or either one of, the patient or caregiver | 3 months |
| Attrition Rate | Will be measured as the percentage of those who reached follow-up compared to those who completed baseline | 3 months |
| Number of patients willing to participate | Determined by the proportion of patients saying yes out of those contacted | 3 months |
| Change in quality of life through The World Health Organization Quality of Life - BREF (WHOQOL-BREF) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in quality of life through The Quality of Life in Alzheimer's Disease (QOL-AD) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in physical functioning through the head shake test (HST) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in physical functioning through the dynamic visual acuity (DVA) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in physical functioning through the modified clinical test of sensory interaction on balance (mCTSIB) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| Change in physical functioning through the dynamic gait index (DGI) | Measured by comparing the test score change from baseline to follow up at 3 months | 3 months |
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D002561 | Cerebrovascular Disorders |
| D002537 | Intracranial Arteriosclerosis |
| D020765 | Intracranial Arterial Diseases |
| D056784 | Leukoencephalopathies |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |